PDAC has a high frequency of inactivation of the CDKN2A (encoding the CDK4/6 inhibitor p16) (in > 80% of cases) and p53 (inducing the CDK2 inhibitor p21) (in 60-70% of cases) genes [3, 4], resulting in activated CDK2/4/6 and accelerated cancer progression. This evidence concerns the gene CDKN2A and cancer.